geisen k - Search Results

Year	Number of Results
1966	3
1967	1
1969	2
1970	3
1971	1
1975	1
1976	1
1978	2
1980	1
1981	2
1982	1
1983	2
1984	1
1985	1
1986	1
1987	1
1988	1
1991	1
1994	1
1995	2
1996	3
2004	2
2020	1
2024	0

1

Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.

Müller G, Satoh Y, Geisen K. Müller G, et al. Among authors: geisen k. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S115-37. doi: 10.1016/0168-8227(95)01089-v. Diabetes Res Clin Pract. 1995. PMID: 8529504 Review.

2

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.

Müller G, Geisen K. Müller G, et al. Among authors: geisen k. Horm Metab Res. 1996 Sep;28(9):469-87. doi: 10.1055/s-2007-979839. Horm Metab Res. 1996. PMID: 8911985 Review.

3

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.

Kramer W, Müller G, Geisen K. Kramer W, et al. Among authors: geisen k. Horm Metab Res. 1996 Sep;28(9):464-8. doi: 10.1055/s-2007-979838. Horm Metab Res. 1996. PMID: 8911984 Review.

4

[(A1-beta-Alanine) insulin].

Geiger R, Geisen K, Regitz G, Summ HD. Geiger R, et al. Among authors: geisen k. Hoppe Seylers Z Physiol Chem. 1976 Sep;357(9):1267-70. doi: 10.1515/bchm2.1976.357.2.1267. Hoppe Seylers Z Physiol Chem. 1976. PMID: 992580 German.

5

Sorbitol-accumulating pyrimidine derivatives.

Geisen K, Utz R, Grötsch H, Lang HJ, Nimmesgern H. Geisen K, et al. Arzneimittelforschung. 1994 Sep;44(9):1032-43. Arzneimittelforschung. 1994. PMID: 7986240

6

Side-by-side comparability of batch and continuous downstream for the production of monoclonal antibodies.

David L, Schwan P, Lobedann M, Borchert SO, Budde B, Temming M, Kuerschner M, Alberti Aguilo FM, Baumarth K, Thüte T, Maiser B, Blank A, Kistler V, Weber N, Brandt H, Poggel M, Kaiser K, Geisen K, Oehme F, Schembecker G. David L, et al. Among authors: geisen k. Biotechnol Bioeng. 2020 Apr;117(4):1024-1036. doi: 10.1002/bit.27267. Epub 2020 Jan 29. Biotechnol Bioeng. 2020. PMID: 31930482

7

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.

Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Hammes HP, et al. Among authors: geisen k. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11555-8. doi: 10.1073/pnas.88.24.11555. Proc Natl Acad Sci U S A. 1991. PMID: 1763069 Free PMC article.

8

Cardiovascular effects of conventional sulfonylureas and glimepiride.

Geisen K, Végh A, Krause E, Papp JG. Geisen K, et al. Horm Metab Res. 1996 Sep;28(9):496-507. doi: 10.1055/s-2007-979841. Horm Metab Res. 1996. PMID: 8911987

9

Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces.

Thurow H, Geisen K. Thurow H, et al. Among authors: geisen k. Diabetologia. 1984 Aug;27(2):212-8. doi: 10.1007/BF00273809. Diabetologia. 1984. PMID: 6386584

10

Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats.

Hammes HP, Ali SS, Uhlmann M, Weiss A, Federlin K, Geisen K, Brownlee M. Hammes HP, et al. Among authors: geisen k. Diabetologia. 1995 Mar;38(3):269-73. doi: 10.1007/BF00400629. Diabetologia. 1995. PMID: 7758871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

35 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year